{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T03:09:45Z","timestamp":1788318585567,"version":"build-2803163510"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"vor","delay-in-days":171,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>This study contributes to the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)\u2019s effort to define \u2018difficult-to-treat\u2019 PsA (D2T-PsA), leveraging insights of healthcare professionals who are GRAPPA members. The primary objective is to inform GRAPPA\u2019s D2T PsA project, ensuring the consensus definition reflects clinical experience and expertise.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>An online survey was conducted among GRAPPA\u2019s healthcare professionals managing PsA patients. The survey covered demographic details, structured questions, and open-ended queries to gather comprehensive insights into the experts\u2019 viewpoints.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>About 223 physicians completed the survey, comprising 179 (80.2%) rheumatologists and 40 (17.9%) dermatologists. The majority, 184 (82.5%), favoured establishing distinct definitions for D2T-PsA and complex-to-manage PsA (C2M-PsA). Furthermore, 202 (90.5%) supported a definition that includes objective inflammation signs (clinical, laboratory, imaging, among others). However, opinions varied on the criteria for prior treatment failures, with most (93, 41.7%) favouring a definition that includes at least one conventional synthetic disease-modifying anti-rheumatic drug and two or more biological- or targeted-synthetic-DMARDs with different mechanisms of action.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The survey reveals a majority opinion among GRAPPA experts favouring the differentiation between D2T-PsA and C2M-PsA, and the inclusion of objective inflammatory markers in these definitions. However, there is less than 50% agreement on the specific treatment failure criteria, particularly regarding the number of therapies needed to classify PsA as D2T. These findings suggest a need for continued discussion to reach a more unified approach in defining D2T-PsA, reflecting the complexity of the condition.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rap\/rkae074","type":"journal-article","created":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:44:15Z","timestamp":1718844255000},"source":"Crossref","is-referenced-by-count":38,"title":["Deciphering difficult-to-treat psoriatic arthritis (D2T-PsA): a GRAPPA perspective from an international survey of healthcare professionals"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6782-8924","authenticated-orcid":false,"given":"Andre L","family":"Ribeiro","sequence":"first","affiliation":[{"name":"Division of Rheumatology, University of Toronto, Women\u2019s College Hospital , Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikha","family":"Singla","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Medical College of Wisconsin , Milwaukee, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Chandran","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, University of Toronto , Toronto, Canada"},{"name":"Psoriatic Arthritis Program, Schroeder Arthritis Institute, University Health Network , Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Chronis","sequence":"additional","affiliation":[{"name":"Psoriatic Arthritis Program, Schroeder Arthritis Institute, University Health Network , Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson","family":"Liao","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California San Francisco , San Francisco, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Lindsay","sequence":"additional","affiliation":[{"name":"GRAPPA Patient Research Partner , Prosper, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3143-1084","authenticated-orcid":false,"given":"Enrique R","family":"Soriano","sequence":"additional","affiliation":[{"name":"Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires , Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J","family":"Mease","sequence":"additional","affiliation":[{"name":"Swedish Medical Center\/Providence St, Joseph Health and University of Washington School of Medicine , Seattle, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4306-033X","authenticated-orcid":false,"given":"Fabian","family":"Proft","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin , Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,6,19]]},"reference":[{"key":"2024062213313171100_rkae074-B1","doi-asserted-by":"crossref","first-page":"101670","DOI":"10.1016\/j.berh.2021.101670","article-title":"Clinical features of psoriatic arthritis","volume":"35","author":"Kishimoto","year":"2021","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2024062213313171100_rkae074-B2","doi-asserted-by":"crossref","first-page":"152237","DOI":"10.1016\/j.semarthrit.2023.152237","article-title":"Treat-to-target in real-life psoriatic arthritis patients: achieving minimal disease activity with bDMARDs\/tsDMARDs and potential barriers","volume":"62","author":"Ortolan","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"2024062213313171100_rkae074-B3","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.clinthera.2023.05.010","article-title":"Pharmacologic treatment strategies in psoriatic arthritis","volume":"45","author":"Ayan","year":"2023","journal-title":"Clin Ther"},{"key":"2024062213313171100_rkae074-B4","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3899\/jrheum.190677","article-title":"Prevalence of psoriatic arthritis patients achieving minimal disease activity in real-world studies and randomized clinical trials: systematic review with metaanalysis","volume":"47","author":"Zardin-Moraes","year":"2020","journal-title":"J Rheumatol"},{"key":"2024062213313171100_rkae074-B5","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1093\/rheumatology\/keaa030","article-title":"Remission and low disease activity in psoriatic arthritis publications: a systematic literature review with meta-analysis","volume":"59","author":"Hag\u00e8ge","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2024062213313171100_rkae074-B6","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.clinthera.2023.04.005","article-title":"Challenges in the management of psoriatic arthritis in Latin America: a systematic review","volume":"45","author":"Ribeiro","year":"2023","journal-title":"Clin Ther"},{"key":"2024062213313171100_rkae074-B7","doi-asserted-by":"crossref","first-page":"101693","DOI":"10.1016\/j.berh.2021.101693","article-title":"Unmet needs in psoriatic arthritis","volume":"35","author":"Ng","year":"2021","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2024062213313171100_rkae074-B8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1136\/annrheumdis-2020-217344","article-title":"EULAR definition of difficult-to-treat rheumatoid arthritis","volume":"80","author":"Nagy","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2024062213313171100_rkae074-B9"},{"key":"2024062213313171100_rkae074-B10","doi-asserted-by":"crossref","first-page":"e003809","DOI":"10.1136\/rmdopen-2023-003809","article-title":"Difficult-to-treat psoriatic arthritis (D2T-PsA): a scoping literature review informing a GRAPPA research project","volume":"10","author":"Singla","year":"2024","journal-title":"RMD Open"},{"key":"2024062213313171100_rkae074-B11","first-page":"52","article-title":"Laboratory findings in psoriatic arthritis","volume":"59","author":"Punzi","year":"2007","journal-title":"Reumatismo"},{"key":"2024062213313171100_rkae074-B12","doi-asserted-by":"crossref","first-page":"e001756","DOI":"10.1136\/rmdopen-2021-001756","article-title":"Systematic review of the use of CRP in clinical trials for psoriatic arthritis: a concern for clinical practice?","volume":"8","author":"Houttekiet","year":"2022","journal-title":"RMD Open"},{"key":"2024062213313171100_rkae074-B13","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.3899\/jrheum.181385","article-title":"Comparing psoriatic arthritis low-field magnetic resonance imaging, ultrasound, and clinical outcomes: data from the TICOPA trial","volume":"47","author":"Helliwell","year":"2020","journal-title":"J Rheumatol"},{"key":"2024062213313171100_rkae074-B14","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3899\/jrheum.190857","article-title":"The pattern of musculoskeletal complaints in patients with suspected psoriatic arthritis and their correlation with physical examination and ultrasound","volume":"48","author":"Sarabia","year":"2021","journal-title":"J Rheumatol"},{"key":"2024062213313171100_rkae074-B15","doi-asserted-by":"crossref","first-page":"904","DOI":"10.3899\/jrheum.171411","article-title":"Ultrasonographic and clinical assessment of peripheral enthesitis in patients with psoriatic arthritis, psoriasis, and fibromyalgia syndrome: the ULISSE study","volume":"46","author":"Macchioni","year":"2019","journal-title":"J Rheumatol"},{"key":"2024062213313171100_rkae074-B16","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2014-206971","article-title":"EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice","volume":"74","author":"Mandl","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2024062213313171100_rkae074-B17","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.semarthrit.2017.10.021","article-title":"Considerations for the definition of remission criteria in psoriatic arthritis","volume":"47","author":"Mease","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"2024062213313171100_rkae074-B18","doi-asserted-by":"crossref","first-page":"762921","DOI":"10.1155\/2013\/762921","article-title":"High frequency of fibromyalgia in patients with psoriatic arthritis: a pilot study","volume":"2013","author":"Magrey","year":"2013","journal-title":"Arthritis"},{"key":"2024062213313171100_rkae074-B19","doi-asserted-by":"crossref","first-page":"887","DOI":"10.3899\/jrheum.130797","article-title":"Depression and anxiety in psoriatic disease: prevalence and associated factors","volume":"41","author":"McDonough","year":"2014","journal-title":"J Rheumatol"},{"key":"2024062213313171100_rkae074-B20","first-page":"426","article-title":"Management of psoriatic arthritis in patients with comorbidities: an updated literature review informing the 2021 GRAPPA treatment recommendations","volume":"50","author":"Campanholo","year":"2023","journal-title":"J Rheumatol"},{"key":"2024062213313171100_rkae074-B21","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s10067-018-4383-9","article-title":"Treating psoriatic arthritis to target: discordance between physicians and patients\u2019 assessment, non-adherence, and restricted access to drugs precluded therapy escalation in a real-world cohort","volume":"38","author":"Ferreira","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2024062213313171100_rkae074-B22","doi-asserted-by":"crossref","first-page":"e0171070","DOI":"10.1371\/journal.pone.0171070","article-title":"Does non-adherence to DMARDs influence hospital-related healthcare costs for early arthritis in the first year of treatment?","volume":"12","author":"Pasma","year":"2017","journal-title":"PLoS One"},{"key":"2024062213313171100_rkae074-B23","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2024062213313171100_rkae074-B24","first-page":"700"},{"key":"2024062213313171100_rkae074-B25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.semarthrit.2017.02.001","article-title":"Switching biologics in the treatment of psoriatic arthritis","volume":"47","author":"Merola","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"2024062213313171100_rkae074-B26","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/ard-2023-225087","article-title":"Time to address the challenge of difficult to treat psoriatic arthritis: results from an international survey","volume":"83","author":"Marzo-Ortega","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2024062213313171100_rkae074-B27","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s40744-022-00461-w","article-title":"Clinical characteristics of potential \u201cdifficult-to-treat\u201d patients with psoriatic arthritis: a retrospective analysis of a longitudinal cohort","volume":"9","author":"Perrotta","year":"2022","journal-title":"Rheumatol Ther"},{"key":"2024062213313171100_rkae074-B28","doi-asserted-by":"crossref","first-page":"105512","DOI":"10.1016\/j.jbspin.2022.105512","article-title":"Is the difficult-to-treat (D2T) concept applicable to axial spondyloarthritis?","volume":"90","author":"Wendling","year":"2023","journal-title":"Joint Bone Spine"},{"key":"2024062213313171100_rkae074-B29","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1007\/s10067-023-06627-3","article-title":"Difficult to treat psoriatic arthritis\u2014how should we manage?","volume":"42","author":"Kumthekar","year":"2023","journal-title":"Clin Rheumatol"},{"key":"2024062213313171100_rkae074-B30","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s40744-023-00574-w","article-title":"Difficult to treat and refractory to treatment in psoriatic arthritis","volume":"10","author":"Lubrano","year":"2023","journal-title":"Rheumatol Ther"},{"key":"2024062213313171100_rkae074-B31","doi-asserted-by":"crossref","first-page":"152275","DOI":"10.1016\/j.semarthrit.2023.152275","article-title":"Characteristics of difficult-to-treat psoriatic arthritis: a comparative analysis","volume":"63","author":"Philippoteaux","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"2024062213313171100_rkae074-B32","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.3899\/jrheum.2023-0424","article-title":"Screening\/referral strategies for the early recognition of psoriatic arthritis (PsA) among patients with psoriasis: results of a GRAPPA survey","volume":"50","author":"Song","year":"2023","journal-title":"J Rheumatol"}],"container-title":["Rheumatology Advances in Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumap\/advance-article-pdf\/doi\/10.1093\/rap\/rkae074\/58281042\/rkae074.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/8\/3\/rkae074\/58305598\/rkae074.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/8\/3\/rkae074\/58305598\/rkae074.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T13:31:56Z","timestamp":1719063116000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumap\/article\/doi\/10.1093\/rap\/rkae074\/7696329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6,7]]}},"URL":"https:\/\/doi.org\/10.1093\/rap\/rkae074","relation":{},"ISSN":["2514-1775"],"issn-type":[{"value":"2514-1775","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024]]},"published":{"date-parts":[[2024]]},"article-number":"rkae074"}}